Zydus Cadila Kickstarts the Supply of ZyCoV-D, It’s Novel Covid-19 Vaccine, to the Government
In a significant stride towards bolstering India’s Covid-19 vaccination drive, pharmaceutical giant Zydus Cadila has commenced the supply of its Covid-19 vaccine, ZyCoV-D, to the government. This development marks a crucial step in the nation’s fight against the ongoing pandemic, opening up a new front in the battle against Covid-19.
ZyCoV-D: A Glimpse into the Vaccine
ZyCoV-D, developed by the Ahmedabad-based pharmaceutical company Zydus Cadila, is the world’s first DNA-based vaccine for Covid-19 approved for emergency use in adults and children aged 12 years and above. The vaccine utilizes a section of genetic material from the SARS-CoV-2 virus that gives the instructions for making the spike protein of the virus. Recognizing this as a foreign entity, the human body mounts an immune response against it.
A Unique Vaccine with Multiple Advantages
One of the most significant advantages of ZyCoV-D is that it can be administered without a needle, which makes it India’s first needle-free Covid-19 jab. It is administered using the PharmaJet needle-free system that delivers the vaccine intradermally by a narrow, precise fluid stream penetrating the skin.
ZyCoV-D is a three-dose vaccine, and it does not require adjuvants to enhance immune responses, making it potentially safer for those with allergies. Moreover, it can be stored and transported at standard refrigeration temperatures, making it a practical option for a country as vast and diverse as India.
The Rollout of ZyCoV-D
Zydus Cadila announced that it has begun supplying ZyCoV-D to the government, marking the vaccine’s rollout in India’s immunization program. The company has geared up to manufacture up to 120 million doses annually and plans to ramp up production over the next few months.
The addition of ZyCoV-D to India’s vaccine arsenal is expected to significantly accelerate the country’s vaccination campaign. With the threat of new variants and the potential for future waves of the virus, the availability of a new vaccine is a positive development.
The start of ZyCoV-D’s supply to the government is a welcome development in India’s ongoing battle against Covid-19. As the world’s first DNA-based Covid-19 vaccine, it brings new hope and adds to the robustness of the country’s vaccination drive. The fight against Covid-19 is far from over, but with each new development like this, victory seems a step closer.